Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Louisiana: - West Jefferson Medical Center — Marrero, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Louisiana: - Investigative Site US007 — New Orleans, Louisiana
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Louisiana: - East Jefferson General Hospital — Metairie, Louisiana
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana
- LSU Health Shreveport — Shreveport, Louisiana
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Louisiana: - Louisiana State University Health Sciences — Metairie, Louisiana
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Louisiana: - Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Louisiana: - Ohio State University Telemedicine — Lake Charles, Louisiana
- Ohio State University-Telemedicine — New Orleans, Louisiana
- Ohio State University Telemedicine — Shreveport, Louisiana
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Louisiana: - Our Lady of the Lake — Baton Rouge, Louisiana
Phase 1, Phase 2 Recruiting Industry
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Sponsor: CivaTech Oncology
NCT ID: NCT02843945
Sites in Louisiana: - University Medical Center LSU — New Orleans, Louisiana
Phase 1 Recruiting Industry
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…
Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in Louisiana: - Ochsner Health — Jefferson, Louisiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Louisiana: - Ochsner Medical Center Jefferson — New Orleans, Louisiana
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Louisiana: - Tulane Cancer Center — New Orleans, Louisiana
- Christus Highland/ Boniol — Shreveport, Louisiana
Recruiting Academic/Other
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Sponsor: City of Hope Medical Center
NCT ID: NCT06388967
Sites in Louisiana: - Ochsner Medical Center — Jefferson, Louisiana